Clinical Trial Update: A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating TAR-200 in combination with cetrelimab or cetrelimab alone in muscle-invasive urothelial carcinoma of the bladder, with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Urothelial Carcinoma of the Bladder
• Urinary Bladder Neoplasms

Drugs mentioned

• Cetrelimab
• TAR-200

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Urinary Bladder Neoplasms | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-02-17